Skip to content

Effects of Ticagrelor on the Clinical consequences of Angioplasty in Myocardial Infarction and Covid-19.d

Evaluation of the Effects of Ticagrelor on the Prognosis of Percutaneous Coronary Interventions in Patients with Covid-19 and Comparing it with Clopidogrel

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220813055675N1
Enrollment
200
Registered
2022-08-16
Start date
2022-08-20
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Ticagrelor drug ("Brilavus" from ABIDI Company) is prescribed orally at the loading dose of 180 mg at the beginning of the patient's visit and before the start of a

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years of age who present with acute myocardial infarction. Candidates for emergent coronary angioplasty ( Percutaneous coronary intervention ) Less than 24 hours have passed since the onset of chest pain symptoms. are infected with the concomitant covid-19 disease (proved by CT Scan or PCR).

Exclusion criteria

Exclusion criteria: Lack of patient consent to perform coronary interventions or enter the study Chronic and necessary use of any anti-coagulant drug by the patient severe renal failure (GFR less than 30) Severe heart failure (EF less than 30%) Age under 18 years old Pregnancy or suspected pregnancy History of intracranial or intraspinal bleeding Administration of any intravenous antiviral drug in the same admision Severe liver failure Past history of any malignancy or chemotherapy regimen

Design outcomes

Primary

MeasureTime frame
Cardiovascular Death. Timepoint: During the index admission, and after 1 month from hospital discharge. Method of measurement: Admission file and follow-up data.

Secondary

MeasureTime frame
Stent Thrombosis. Timepoint: During index admission and 1 month after discharge. Method of measurement: Coronary Angiography.;Myocardial Infarction. Timepoint: During index admission and 1 month after discharge. Method of measurement: Troponin measurement and Electrocardiography.;Arterial O2 saturation. Timepoint: During the index admission. Method of measurement: Pulse-Oxymetry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Arefi Zade

Artesh University of Medical Sciences

arefizadehreza@yahoo.com+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026